Lentiviral Vectors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Market Insights and Trends

The lentiviral vectors market is poised for remarkable expansion, according to recent industry analysis. With a valuation of US$ 160 million in 2024 and a projected compound annual growth rate (CAGR) of 14% over the next decade, the market is set to reach an impressive US$ 400 million by 2031. Kits, constituting three-fourths of the market share, emerged as a dominant product segment in 2023. Lentiviral vectors' consumption accounted for a substantial 20.1% share of the global viral vectors manufacturing market in 2023.

Unveiling Opportunities for Lentiviral Vector Manufacturers

One of the most significant opportunities lies in the surge in demand for lentiviral vectors in T cell engineering for cancer treatment. Lentiviral vectors have become instrumental in gene-modified cell-based therapies, particularly in the realm of T cell therapies. These vectors play a crucial role in conveying Chimeric Antigen Receptors (CARs) or cloned T-cell receptors to mature T cells, facilitating the creation of anti-cancer immunity. Notably, the FDA's approval of the first genetically-engineered cellular therapy underscores the clinical effectiveness lentiviral vectors bring to patients with B-cell malignancies.

Moreover, lentiviral vectors continue to evolve alongside CAR T-cell therapy, demonstrating their potential as a potent supplementary tool in treating a broader spectrum of malignancies. The evolving landscape presents numerous opportunities for lentiviral vector manufacturers, particularly in emerging economies, where business expansion prospects are ripe.

Challenges in Market Expansion

Despite the promising growth trajectory, challenges persist, primarily concerning the high cost of gene therapy. While gene therapy holds immense potential in curing various illnesses and enhancing the body's ability to combat diseases, its cost remains a significant barrier. Gene therapy pricing, often determined on a case-by-case basis, lacks regulation, leading to substantial upfront payments. Factors such as development costs, disease characteristics, and associated expenses further complicate pricing strategies, potentially hindering market expansion.

Country-wise Insights

United States: Target for Strategic Acquisitions

The U.S. dominates the North America lentiviral vectors market, accounting for a significant 82% of its value. This high market share is attributed to the presence of major industry players within the country, ensuring ample product availability. Notably, strategic acquisitions and mergers among key players are driving market growth. For instance, in June 2021, Charles River Laboratories International, Inc. acquired Vigene Biosciences, Inc., enhancing its viral vector-based gene delivery solutions.

United Kingdom: Research Hub for Cancer Treatment

In the United Kingdom, the lentiviral vectors market held a substantial market share of 25.2% in Europe in 2021. The country stands as a hub for research activities, particularly in cancer treatment. Researchers in the UK are actively exploring the use of lentiviral vectors for T cell engineering to uncover novel cancer therapeutic options. These vectors, proven to be safe and effective for gene transfer, are integral to the advancement of CAR T cell treatments, contributing to the rapid expansion of the market in the UK.

China: Emerging Manufacturing Powerhouse

China is emerging as a prominent market for lentiviral vectors, accounting for 37.1% of the lentiviral vectors market share in East Asia. The region's rapid development of medical infrastructure and strategic planning for expansion are driving factors behind its flourishing lentiviral vectors industry. Notably, companies like GenScript ProBio are contributing to this growth with the construction of new manufacturing facilities, such as its 34,000-square-meter GMP manufacturing facility in Zhenjiang, Jiangsu. This underscores China's position as a key player in the global lentiviral vectors market.

Competitive Analysis and Key Players

Strategic collaborations, product launches, and acquisitions are central to increasing market presence among key lentiviral vector manufacturers. Companies such as Thermo Fisher Scientific, PerkinElmer Inc. (Sirion-Biotech GmbH), GENEMEDI, Takara Bio, Inc., Charles River Laboratories, Sino Biological Inc., OriGene Technologies, Inc., Cell BioLabs, Inc., and Applied Biological Materials Inc. are actively engaged in developing innovative lentiviral vector solutions to capture larger market shares.

• Thermo Fisher Scientific
• PerkinElmer Inc. (Sirion-Biotech GmbH)
• GENEMEDI
• Takara Bio, Inc.
• Charles River Laboratories
• Sino Biological Inc.
• OriGene Technologies, Inc.
• Cell BioLabs, Inc.
• Applied Biological Materials Inc.

Key Segments Covered in Lentiviral Vectors Industry Survey

Lentiviral Vectors Market by Product:

• Lentiviral Vector Kits
• Lentiviral Packing Systems
• Lentiviral Expression Systems
• Lentiviral Promoter Kits
• Lentiviral Fusion Tags
• Reagents & Consumables

Lentiviral Vectors Market by Indication:

• Cancer
• Genetic Disorders
• Infectious Diseases
• Veterinary Diseases
• Others

Lentiviral Vectors Market by End User:

• Biotechnology Companies
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes

Lentiviral Vectors Market by Region:

• North America Lentiviral Vectors Market
• Latin America Lentiviral Vectors Market
• Europe Lentiviral Vectors Market
• South Asia Lentiviral Vectors Market
• East Asia Lentiviral Vectors Market
• Oceania Lentiviral Vectors Market
• Middle East & Africa Lentiviral Vectors Market

This product will be delivered within 1-3 business days.